Fujisawa’s gallium nitrate
Executive Summary
Demonstrates a 92% efficacy rate in controlling cancer-related hypercalcemia, according to results from a double-blind randomized trial reported by Raymond Warrell, MD, Sloan-Kettering Cancer Center, at a recent meeting of the American Society of Clinical Oncology. Gallium nitrate was compared to etidronate (MGI Pharma's Didronel IV), which produced only a 44% rate of normal calcium blood levels in hypercalcemic patients.
Demonstrates a 92% efficacy rate in controlling cancer-related
hypercalcemia, according to results from a double-blind randomized
trial reported by Raymond Warrell, MD, Sloan-Kettering Cancer
Center, at a recent meeting of the American Society of Clinical
Oncology. Gallium nitrate was compared to etidronate (MGI Pharma's
Didronel IV), which produced only a 44% rate of normal calcium
blood levels in hypercalcemic patients. |